logo
NasdaqGS:RGNX logo

REGENXBIO Community

NasdaqGS:RGNX Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

RGNX logo
REGENXBIO
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts

FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline

Key Takeaways Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments. Advancements in pivotal trials and robust financing options position the company for long-term revenue and market share expansion.
View narrative
US$32.50
FV
70.0% undervalued intrinsic discount
51.74%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
6 days ago author updated this narrative